FDA Readies ICH Q12 Implementation Guidance, Learns Lessons From Pilot
Executive Summary
Upcoming ICH Q12 implementation guidance will translate terminology on post-approval changes into a US context, said a US FDA official who also shared some lessons learned on established conditions.
You may also be interested in...
Generics Firms Seek To Establish Better Conditions For Post-Approval Change Flexibility
Concerns raised around defining ICH Q12 “established conditions” for post-approval changes and potential role of prior knowledge for legacy products discussed in the context of generic drug applications; likely residual lack of harmonization explored.
Generics Firms Seek To Establish Better Conditions For Post-Approval Change Flexibility
Concerns raised around defining ICH Q12 “established conditions” for post-approval changes and potential role of prior knowledge for legacy products discussed in the context of generic drug applications; likely residual lack of harmonization explored.
Industry Urged To Use ICH Q12 Protocols To Ease Post-Approval Changes For Analytical Methods
Post-approval change management protocols could go a long way toward smoothing global rollout of analytical method changes, ICH Q12 expert says.